✦ LIBER ✦

A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer

✍ Scribed by Patrick B. Murphy; John D. Hainsworth; F. Anthony Greco; Kenneth R. Hande; Russell F. Devore; David H. Johnson

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 582 KB
Volume: 69
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19920115)69:2<370::aid-cncr2820690217>3.0.co;2-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of carboplatin in untre

A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer

✍ Cinta Pallares; Miguel Angel Izquierdo; Alfredo Paredes; Alberto Fernandez Sagar 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 2 views

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study

✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 1 views

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin

Cisplatin and etoposide (VP-16) as a sin

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial

✍ Corrado Boni; Giorgio Cocconi; Giancarlo Bisagni; Guido Ceci; Giuseppe Peracchia 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB 👁 2 views

Phase II trial of irinotecan, cisplatin

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 87 KB 👁 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Alternating chemotherapy with etoposide

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma : A Phase II trial of the North Central Cancer Treatment Group

✍ James R. Jett; Alan K. Hatfield; Shauna Hillman; Michael D. Bauman; James A. Mai 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

## Abstract ## BACKGROUND The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive‐stage small cell lung carcinoma (SCLC). ## METHODS Patients with histologically proven, extensive‐stage SCLC, with a perfor